key: cord-0703556-sh4ugevs
authors: Bernstein, Charles N; Singh, Harminder; Murthy, Sanjay K; Nguyen, Geoffrey C; Benchimol, Eric I; Bitton, Alain; Kuenzig, M Ellen; Huang, James Guoxian; Jones, Jennifer L; Lee, Kate; Targownik, Laura E; Windsor, Joseph W; Mukhtar, Mariam S; Tandon, Parul; Kaplan, Gilaad G
title: Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD
date: 2021-11-05
journal: J Can Assoc Gastroenterol
DOI: 10.1093/jcag/gwab025
sha: c18ff9e66e86fdeee5c64e7f092983a9d200e57d
doc_id: 703556
cord_uid: sh4ugevs

The risk of hospitalization and death from Coronavirus disease-19 (COVID-19) increases with age. The extreme elderly have been particularly vulnerable, with those above the age of 80 having a case-fatality rate as high as 15%. Aging of the immune system can lead to impaired inflammatory responses where eradication of an organism such as Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) is inadequate but is exaggerated in such a way as to enhance pneumonia and acute respiratory distress syndrome. Frailty and comorbidity are both more common in the elderly, and these can enhance the morbidity and mortality from COVID-19. Studies from Northern California and Italy suggest that elderly persons with inflammatory bowel disease (IBD) were more likely to acquire SARS-CoV-2 infection than youths with IBD. While the specific impact of age-related comorbidity is less well established among people with IBD who acquire COVID-19, data from the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) database reported that having two or more chronic illnesses was independently associated with developing severe COVID-19 among people with IBD. Despite having exaggerated auto-inflammatory responses, people with IBD do not appear to have an overall increased risk of developing severe COVID-19 than the general population. However, whether seniors with IBD do worse once they acquire COVID-19 compared with seniors without IBD is not known. The advent of telehealth care has posed an information technology challenge for many seniors with and without IBD. Most persons with IBD have expressed satisfaction with virtual IBD health care (phone or video-based visits). While the elderly may have less robust immune responses to vaccinations, learning from experiences with other vaccination programs, especially influenza, have shown that vaccinating seniors decreases both morbidity and mortality and, in turn, healthcare resources.

Seniors represent the Fastest-growing demographic with IBD in Canada with nearly 1 in 160 Canadians above the age of 65 affected (1, 2) . Every day, new diagnoses of IBD are being made in seniors, and the prevalent IBD population is aging. Consequently, gastroenterology clinics today are contending with an older population and having to balance care of IBD with age-related comorbidities, such as diabetes, cardiovascular disease (CVD) and dementia (3) . Understandably, the Coronavirus disease-19 (COVID-19) pandemic created significant anxiety among seniors with IBD as the morbidity and mortality of COVID-19 disproportionately impacted those of advanced age. This section reviews the impact of COVID-19 on people with IBD living in Canada.

The risk of hospitalization and death from COVID-19 increases with age (4) (5) (6) . In the first half of the COVID-19 pandemic in the United States, people above 65 years of age comprised 45% of hospitalizations, 53% of intensive care unit admissions and 80% of deaths associated with COVID-19, despite comprising just 17% of the population (7) . The extreme elderly have been particularly vulnerable, with those above the age of 80 having a case-fatality rate as high as 15% (8) . Immune aging, frailty, and comorbid illnesses may all contribute toward an increased risk of adverse COVID-19-related outcomes among the elderly.

Immune aging (immunosenescence) refers to age-related changes that tip the balance of immunity in favour of proinflammatory pathways. The expression of angiotensin-converting enzyme 2 (ACE2), which converts angiotensin II to angiotensin, decreases with age and with CVD (9) (10) (11) . Angiotensin II has pro-inflammatory properties that may mediate acute lung injury through vasoconstriction and increased vascular permeability. ACE2 is expressed in the lung, heart, kidney, blood vessels, brain, intestine and fat tissue. As ACE2 is also the receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (12) , reduced ACE2 expression in these organs could lead to exaggerated inflammatory responses in the elderly in response to SARS-CoV-2 infection, especially in those with CVD.

Aging is also characterized by chronic, low-grade inflammation with a relative increase in the production of proinflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α (TNF-α) (13, 14) . Severe cases of COVID-19, including people requiring intensive care admission, showed higher levels of TNF-α, among other proinflammatory cytokines like IL-6 (15, 16) . Aging may further be associated with reduced levels of type I interferons (i.e., interferons α and β); these are important for lowering the susceptibility of cells neighboring virus-infected cells from viral entry and replication as well as for activating natural killer cells and Th1-lymphocytes, which amplify the anti-viral response (17) (18) (19) . Together, these pro-inflammatory changes might contribute to the development of acute respiratory distress syndrome and multi-organ failure in the elderly (20) .

Frailty, as reflected by reduced physiologic reserve due to comorbidities, bone and muscle atrophy, decreased physical activity and reduced cognition, is more prominent in seniors. Greater frailty is associated with increased mortality and morbidity, particularly in the setting of systemic infection (21) (22) (23) (24) . Frailty has also been correlated with higher levels of IL-6, TNF-α and C-reactive protein, suggesting an association with a pro-inflammatory state (25, 26) . These frailty factors may place elderly persons at further risk of severe outcomes with COVID-19 infection.

Pre-existing CVD, chronic lung disease, hypertension, diabetes and obesity, which are observed more often in seniors, have all been associated with more severe COVID-19 (8, (27) (28) (29) . While the relationships between these conditions and severe COVID-19 are not well understood, it stands to reason that

• Seniors have the highest risk of severe COVID-19 in the general population and among those with IBD. • Senescence of the immune system and comorbidities both enhance the morbidity and mortality from COVID-19 among the elderly.

• Seniors with IBD do not have an increased risk of acquiring SARS-CoV-2 and share a similar risk of complications from COVID-19 as compared to seniors without IBD.

• Telehealth care has been an important mechanism for seniors with and without IBD to maintain contact with their healthcare providers and ensure their care unrelated to COVID-19 is minimally compromised by the pandemic.

• While seniors may have less robust immune responses to vaccinations, experiences with other vaccination programs, especially influenza, have shown that vaccinating seniors decreases both morbidity and mortality and, in turn, healthcare resources.

Journal of the Canadian Association of Gastroenterology, 2021, Vol. 4, No. S2 S35 they may predispose to impaired adaptive immunity, increase in pro-inflammatory cytokines and poorer vascular and respiratory reserve to combat infection, leading to greater viral replication, maladaptive immune responses, overwhelming inflammation and multi-organ failure. Furthermore, in the context of greater atherosclerotic disease, severe COVID-19 infection may increase the risk of cardiac and neurologic complications, such as stroke and myocardial infarction (30) (31) (32) (33) (34) . Additionally, COVID-19 is associated with an increase in arterial and venous thrombotic complications, which may be even more pronounced in the elderly due to underlying atherosclerotic disease (35) (36) (37) .

A growing proportion of people with IBD are elderly, and this already vulnerable group may shoulder the brunt of the risk from COVID-19. Despite physical isolation, seniors with IBD seemed to have managed relatively well with respect to mental health compared with younger persons with IBD. The brave new realm of virtual medicine that evolved during the COVID-19 pandemic has also introduced new challenges for the elderly as well as opportunities.

As in the general population, the risk of severe COVID-19 and disease-related mortality is increased in seniors with IBD (38) . Certain chronic diseases also increase the risk of COVID-19 severity. Reassuringly, a Swedish population-based study showed that IBD diagnosis among those aged ≥60 years neither increased the risk of hospitalization with COVID-19 nor COVID-19 severity compared with the general population (39) . While the specific impact of age-related comorbidity is less well established among people with IBD who acquire COVID-19, data from the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) registry suggest that having two or more chronic illnesses was independently associated with developing severe COVID-19 among people with IBD (e.g., CVD, diabetes, lung disease, hypertension, cancer, history of stroke, chronic kidney disease, chronic liver disease and others) (38) . Studies from Italy and the Netherlands have similarly shown that comorbidity burden is an independent predictor of adverse COVID-19 outcomes among people with IBD (40, 41) . Notably, despite having exaggerated autoinflammatory responses, persons with IBD do not appear to have an overall increased risk of developing severe COVID-19 than the general population (38, (42) (43) (44) . However, a study from Northern California did suggest that persons with IBD older than 66 years were more likely to acquire SARS-CoV-2 infection than younger persons with IBD (45) . Another Italian study also showed that elderly persons with IBD (≥65 years) had a nearly sixfold higher risk of acquiring COVID-19related pneumonia compared with non-elderly persons with IBD (40) . Seniors with IBD, in general, are less likely to be on immunosuppressants, though corticosteroid use is similar (46) . Data from the SECURE-IBD registry suggest that while the use of corticosteroids and thiopurines did increase the risk of severe COVID-19, the use of biologics, especially anti-TNF agents, may be protective (47) . Overall, IBD diagnosis does not appear to increase the risk of SARS-CoV-2 infection or severe COVID-19 in the elderly population by itself.

The COVID-19 pandemic has also had a substantial impact on the mental health of people with IBD in general, with the majority citing negative impact on mood, anxiety and sleep. Interestingly, in a survey from the United Kingdom, individuals with IBD aged above 55 years were more likely to experience a positive psychosocial impact (48) . In another Australian survey of people with IBD, younger age was actually associated with a greater prevalence of depression and anxiety (49) . Thus, despite social isolation, elderly persons with IBD seemed to have coped better relative to their younger counterparts.

Beyond the immediate risk posed by COVID-19 to seniors with IBD, another challenge has been accessing continued medical care during lockdowns and business occupancy limits. Throughout the course of the COVID-19 pandemic, IBD health services have transitioned to virtual care throughout most of Canada. Most of the persons with IBD have expressed satisfaction with virtual IBD health care (phone or video-based visits) (50, 51) . For older persons with IBD, adapting to new technology may have posed a substantial challenge. However, the flexibility to utilize phone visits and a variety of public, video-based platforms (e.g., Facetime, Skype and Zoom) has made this transition easier. Many individuals with IBD and physicians have expressed a desire to continue telemedicine beyond the pandemic, and this may benefit the elderly with IBD who may have baseline limited mobility.

Similar to COVID-19, the vast majority of seasonal influenza infections and related deaths from the disease occur among the elderly. A Dutch study between 1967 and 1989 reported that 95% of influenza-related mortality occurred among people above 60 years of age (52) . Hence, seniors are a critical group to vaccinate against COVID-19. However, with senescence of the immune system, especially after the age of 60, there is the potential for reduced response to vaccines (53) . What to expect in the elderly population from COVID-19 vaccines can be drawn from previous studies on influenza vaccine experiences.

Some studies have suggested that influenza vaccination may be less effective among subgroups of senior populations. For example, a multicentre study suggested that influenza vaccine effectiveness is lessened among frail older adults (54) . Influenza outbreaks have been reported in nursing homes with excellent vaccine coverage (55) . However, even with a lower vaccine efficacy, influenza vaccines prevent a large number of hospitalizations, intensive care unit admissions and deaths in the older adult population. For example, in a modelling study, during the 2012-2013 influenza season, a vaccine with 10% effectiveness and 66% coverage was estimated to avert approximately 13,000 hospitalizations among individuals ≥65 years of age in the United States; a vaccine with 40% effectiveness and the same coverage was estimated to avert 60,000 hospitalizations (56) . A systematic review for the Cochrane collaboration reported that older adults receiving the influenza vaccine experience less influenza over a single season (2.4% from 6% [Risk Ratio: 0.42; 95% confidence interval: 0.27,0.66]) (57) .

On the one hand, similar results of lower efficacy among individuals above 80 years have been reported for pneumococcal vaccination (58) . On the other hand, the herpes zoster vaccine efficacy is minimally affected by age (59) . Additionally, individuals with IBD-particularly those treated with combination thiopurines and tumor necrosis antagonist therapyhave impaired immunologic response to vaccines, including against influenza (60) . There are, however, no differences in adverse effects among vaccinated individuals with or without IBD (61) . The CLARITY-IBD study evaluated a subpopulation of individuals with IBD who were above the age of 60 and vaccinated with messenger ribonucleic acid (mRNA) or nonviral vector vaccine. Age above 60 years was an independent predictor of lower anti-SARS-CoV-2 antibodies (62) .

Extrapolating from these findings, the effectiveness of COVID-19 vaccination among the elderly with IBD may be lower than among younger individuals, particularly compared with those without IBD. However, substantial benefits are likely to occur. A necessary strategy to improve benefits among elderly individuals with IBD is going to be avoiding delays in receiving the second dosage.

The COVID-19 pandemic has disproportionately impacted the senior population. Those with IBD who are elderly may be at increased risk of acquiring SARS-CoV-2 infection and, like the general population, have similarly higher risk of more severe disease and mortality. Despite these risks, seniors with IBD seemed to have fared no worse-if not better-than their younger IBD counterparts from a mental health perspective. Most have adapted reasonably well to virtual care, and there is an opportunity to continue some aspects of these transformative models of healthcare delivery to address the specific needs of this population post pandemic.

Past and future burden of inflammatory bowel diseases based on modeling of population-based data

The impact of inflammatory bowel disease in Canada 2018: IBD in seniors

The four epidemiological stages in the global evolution of inflammatory bowel disease

Dutch National Institute for Public Health and the Environment

Estimates of the severity of coronavirus disease 2019: A model-based analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study

COVID-19 and older adults: What we know

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention

Age-and gender-related difference of ACE2 expression in rat lung

Age-associated changes in the vascular reninangiotensin system in mice

The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: Insights from Cardiovascular Aging Science

Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus

Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases

Immunosenescence and inflamm-aging as two sides of the same coin: Friends or foes? Front Immunol

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

How does SARS-CoV-2 targets the elderly patients? A review on potential mechanisms increasing disease severity

19: Consider cytokine storm syndromes and immunosuppression

Association between frailty and shortand long-term outcomes among critically ill patients: A multicentre prospective cohort study

VIP1 study group. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years)

Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: An observational study

ELF Study Group. Frailty in older patients undergoing emergency laparotomy: Results from the UK Observational Emergency Laparotomy and Frailty (ELF) Study

Interleukin-6, C-reactive protein, and tumor necrosis factor-alpha as predictors of mortality in frail, community-living elderly individuals

Inflammation and frailty in the elderly: A systematic review and meta-analysis

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Host susceptibility to severe COVID-19 and establishment of a host risk score: Findings of 487 cases outside Wuhan

Obesity is a risk factor for severe COVID-19 infection: Multiple potential mechanisms

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Acute infection and myocardial infarction

COVID-19 and cardiovascular disease

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: A UK-wide surveillance study

The unique characteristics of COVID-19 coagulopathy

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: A multicentre observational study

but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an International Registry

Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden. United

Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study

Clinical outcomes of Covid-19 in patients with inflammatory bowel disease: A nationwide cohort study

COVID-19 in patients with inflammatory bowel disease

Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population

Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the United States: A multicenter research network study

SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California

Medication utilization and the impact of continued corticosteroid use on patient-reported outcomes in older patients with inflammatory bowel disease

Effect of IBD medications on COVID-19 outcomes: Results from an International Registry

Life in lockdown: Experiences of patients with IBD during COVID-19

Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey

Care of inflammatory bowel disease patients during coronavirus disease-19 pandemic using digital health-care technology

Innovation in IBD care during the COVID-19 pandemic: Results of a cross-sectional survey on patient-reported experience measures

Impact of influenza on mortality in relation to age and underlying disease, 1967-1989

Vaccination in the elderly: The challenge of immune changes with aging

Serious Outcomes Surveillance Network of the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) and the Toronto Invasive Bacterial Diseases Network (TIBDN). The importance of frailty in the assessment of influenza vaccine effectiveness against influenza-related hospitalization in elderly people

Detection and control of influenza outbreaks in well-vaccinated nursing home populations

Modeling the effect of different vaccine effectiveness estimates on the number of vaccine-prevented influenza-associated hospitalizations in older adults

Vaccines for preventing influenza in the elderly

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine

Vaccines for older adults

Vaccination in the elderly and IBD

Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Journal of the Canadian Association of Gastroenterology, 2021, Vol. 4, No. S2